Magnesium–Phenolic Nanoeditor Refining Gliomatous T Cells for Metalloimmunotherapy
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide More than the sparse infiltration in glioblastoma, cytotoxic T lymphocytes (CTLs) also function inefficiently and overexpress the inhibitory markers, especially the identified NK cell receptor (NK1.1). However, most studies solely focus on how to augment tumor-infiltrating CTLs and overlook their killing maintenance. Metalloimmunotherapy has been proven to improve the functionalities of CTLs, but it has barely adapted to glioblastoma due to the severe limitations of safe delivery and the brain’s physiological properties. Herein, we synthesized an amphipathic polyethylene glycol (PEG) polymer (designated as MPP) modified with the choline analogue 2-methacryloyloxyethyl phosphorylcholine (MPC) and polyphenol moieties to customize a nanoeditor (Mg 2+ @MK-8931@MPP) by coordinating Mg 2+ and entrapping the hydrophobic BACE1 inhibitor MK-8931, then precisely redressing the gliomatous CTL sparsity and cytotoxic dysfunction. Upon MPC-assisted local accumulation in glioblastoma, Mg 2+ @MK-8931@MPP nanoeditors release MK-8931 to repolarize M2-like macrophages, facilitating CTL infiltration quantitatively. The cenogenetic immune adjuvant Mg 2+ ulteriorly fortifies the T-cell receptor downstream signals to enhance the functionality of the ingoing CTLs in quality, leading to the secretion of high-level antitumor cytokines and cytotoxic proteins. Further blocking the inhibitory NK1.1 on CTLs by anti-NK1.1 antibodies can extend their cytolytic endgame. Studies on T-cell-deficient and wild-type mouse models support the immunomodulating feasibility of Mg 2+ @MK-8931@MPP. This gliomatous CTL-tailored strategy concurrently broadens metalloimmunotherapy to glioblastoma treatment and highlights the necessity of enforcing gliomatous CTLs’ functionality.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune cells in cancer · Immune Cell Function and Interaction · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR 999078, China
MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR 999078, China
Funding
Universidade de Macau · Fundo para o Desenvolvimento das Ci?ncias e da Tecnologia · National Natural Science Foundation of China · Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau
References (51)
Show source-provided references
1. 10.1038/s41586-020-2209-910.1038/s41586-020-2209-9 ↗
2. 10.3322/caac.2161310.3322/caac.21613 ↗
3. 10.1158/1078-0432.CCR-18-162710.1158/1078-0432.CCR-18-1627 ↗
4. 10.1038/nn.418510.1038/nn.4185 ↗
5. 10.1016/j.ccell.2017.02.00910.1016/j.ccell.2017.02.009 ↗
6. 10.1215/15228517-2008-10410.1215/15228517-2008-104 ↗
7. 10.1038/s41568-021-00397-310.1038/s41568-021-00397-3 ↗
8. 10.1038/nm.335510.1038/nm.3355 ↗
9. 10.1038/s43018-021-00267-910.1038/s43018-021-00267-9 ↗
10. 10.1056/NEJM20010301344090710.1056/NEJM200103013440907 ↗
11. 10.1158/1078-0432.CCR-18-004710.1158/1078-0432.CCR-18-0047 ↗
12. 10.1158/1078-0432.CCR-15-151610.1158/1078-0432.CCR-15-1516 ↗
13. 10.1038/s41590-019-0433-y10.1038/s41590-019-0433-y ↗
14. 10.1158/2159-8290.CD-20-180810.1158/2159-8290.CD-20-1808 ↗
15. 10.1038/s41582-018-0025-810.1038/s41582-018-0025-8 ↗
16. 10.1038/nrc323910.1038/nrc3239 ↗
17. 10.1038/s41565-021-00962-910.1038/s41565-021-00962-9 ↗
18. 10.1038/s41551-024-01221-710.1038/s41551-024-01221-7 ↗
19. 10.1038/s41565-022-01225-x10.1038/s41565-022-01225-x ↗
20. 10.1016/S1474-4422(21)00238-610.1016/S1474-4422(21)00238-6 ↗
21. 10.1016/S1474-4422(14)70190-510.1016/S1474-4422(14)70190-5 ↗
22. 10.1152/physrev.00012.201410.1152/physrev.00012.2014 ↗
23. 10.1016/j.cell.2021.12.03910.1016/j.cell.2021.12.039 ↗
24. 10.1016/j.it.2016.11.00510.1016/j.it.2016.11.005 ↗
25. 10.1016/j.cell.2021.01.02210.1016/j.cell.2021.01.022 ↗
26. 10.1126/scitranslmed.adf530210.1126/scitranslmed.adf5302 ↗
27. 10.1002/adma.20180755710.1002/adma.201807557 ↗
28. 10.1021/acsnano.1c0812010.1021/acsnano.1c08120 ↗
29. 10.1016/0092-8674(92)90030-G10.1016/0092-8674(92)90030-G ↗
30. 10.1016/j.nantod.2022.10140510.1016/j.nantod.2022.101405 ↗
31. 10.1016/j.mtsust.2022.10020310.1016/j.mtsust.2022.100203 ↗
32. 10.1002/anie.20231292510.1002/anie.202312925 ↗
33. 10.1016/j.jhazmat.2021.12648710.1016/j.jhazmat.2021.126487 ↗
34. 10.1021/acs.chemmater.1c0417010.1021/acs.chemmater.1c04170 ↗
35. 10.1007/s10570-019-02681-w10.1007/s10570-019-02681-w ↗
36. 10.1016/j.jma.2021.07.01310.1016/j.jma.2021.07.013 ↗
37. 10.1021/acsami.9b1722110.1021/acsami.9b17221 ↗
38. 10.1021/jacs.2c0505210.1021/jacs.2c05052 ↗
39. 10.1016/j.saa.2015.07.05010.1016/j.saa.2015.07.050 ↗
40. 10.1021/jacs.2c1351510.1021/jacs.2c13515 ↗
41. 10.1177/221106821456102510.1177/2211068214561025 ↗
42. 10.1016/S0169-409X(98)00083-010.1016/S0169-409X(98)00083-0 ↗
43. 10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗
44. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
45. 10.1038/s41573-022-00520-510.1038/s41573-022-00520-5 ↗
46. 10.1126/science.124245410.1126/science.1242454 ↗
47. 10.1016/S1074-7613(02)00323-010.1016/S1074-7613(02)00323-0 ↗
48. 10.1074/jbc.M30268620010.1074/jbc.M302686200 ↗
49. 10.1128/mcb.14.3.1680-1688.199410.1128/mcb.14.3.1680-1688.1994 ↗
50. 10.1126/scitranslmed.301064110.1126/scitranslmed.3010641 ↗
51. 10.1146/annurev.immunol.22.012703.10470210.1146/annurev.immunol.22.012703.104702 ↗